Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...
MedPage Today on MSN
Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis
ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...
The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, ...
That’s why we need Senate Bill 41, authored by Sen. Scott Wiener, D-San Francisco, which will require a more fair and ...
Korean biosimilar giant Celltrion announced Monday it has received additional approval from the US Food and Drug ...
Biosimilars saved Italy €3.1 billion in drug spending over a decade as uptake reached 80% of biologic use, according to the ...
I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Stocks rose to begin a busy week that will see a flurry of corporate earnings reports, with investors also awaiting further ...
The rollout of a drug recommended by the National Institute of Health and Care Excellence is 'really exciting' news for UK ...
The stock is trading at $5.69, up 2.92, gaining 105.40% on volume of over 61 Million shares. The stock had a morning high of ...
Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback